{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27"}]}],"title":"Year 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33"}]}],"title":"Year 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"147"}],"units":"Participants"}],"description":"Percent of subjects with non-relapse mortality two years after conditioning with busulfan with fludarabine/200 cGy TBI in patients with hematologic malignancies at moderate to high risk for graft rejection and/or relapse of underlying disease.","groups":[{"description":"Busulfan 3.2 mg/kg IV on day -5 Fludarabine 30 mg/m2/day x 3 (total dose 90 mg/m2, day -4 to day -2 TBI 200 centigray (cGy) x 1, day 0\n\nTherapeutic allogeneic lymphocytes: A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species.\n\nBusulfan: Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative.\n\nIV Busulfan is available and diluted and administered per package insert guidelines.\n\nCyclosporine: Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including","id":"OG000","title":"Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Two years post-transplant","title":"Non-relapse Mortality","type":"PRIMARY","unitOfMeasure":"Participants"}